NASDAQ
Ultragenyx Pharmaceutical Inc. (RARE)
♥ 448 Thanks from members
Ultragenyx (RARE) demonstrates robust commercial growth and a narrower net loss in Q2 2026, highlighted by the milestone accelerated approval of its first gene therapy, GENGLYCOS (DTX401), for GSDIa alongside a valuable Priority Review Voucher.